KALA News and Press, Kala Pharmaceuticals Inc. From 03/29/22

Kala Pharmaceuticals, Inc. (KALA) Q4 2021 Earnings Conference Call March 29, 2022 08:00 ET Company Participants Jill Steier - Executive Director, Investor Relations and Corporate Communications Mark Iwicki - Chairman and Chief Executive Officer Todd Bazemore - President and Chief Operating Of...

Kala Pharmaceuticals (KALA -13.4%) stock following its Q4 results, which missed to beat analysts' estimates. Q4 net revenues decreased -17.07% Y/Y to ~$1.9M. The total consisted of $1.2M from EYSUVIS  and $0.7M from INVELTYS. The company said EYSUVIS net revenue increased by $0.9M in Q4 ...

Gainers: IGM Biosciences IGMS +37%. TRxADE HEALTH MEDS +21%. Ginkgo Bioworks DNA +14%. NexImmune NEXI +13%. BioSig Technologies (BSGM) +8%. Losers: NeoGenomics NEO -34%. Progenity PROG -25%. Aveanna Healthcare (AVAH) -21%. Kala Pharmaceuticals...

NeoGenomics (NEO) -29% on Q1 guidance cut; CEO to quit Progenity (PROG) -22% on Q4 earnings release. Stryve Foods (SNAX) -21% releases inaugural shareholder report. Kala Pharmaceuticals (KALA) -19% on Q4 earnings release. Lipocine (LPCN) -15% its partne...

Kala Pharmaceuticals press release (NASDAQ:KALA): Q4 GAAP EPS of -$0.68 misses by $0.29. Revenue of $1.86M (-17% Y/Y) misses by $1.55M. As of December 31, 2021, cash and cash equivalents of $92.1 million, compared to $124.5 million of cash, cash equivalents and short-term investments as of Se...

-- Achieved $11.2 Million in Net Revenue in 2021 -- -- Expanded Coverage for EYSUVIS ® to 118 Million Commercial Lives and 7.1 Million Medicare Lives -- -- KPI-012 Phase 1b Clinical Data Accepted for Presentation at ARVO; Initiation of Phase 2/3 Clinical Trial of KPI-...

ASO, BGRY, CONN, DPRO, EH, ESLT, HUMA, KALA, LODE, LOVE, MKC, SCYX, UXIN For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open

OKYO Pharma is a UK based developer of next generation ocular therapeutics based on GPCR and MRGPR. The company plans direct Phase 2 trial of its lead candidate following a pre-IND meeting with FDA. The company has filed F-1 for an IPO of its ADSs. For further details see: ...

ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth...

Volt Information Sciences (NYSE:VOLT) +96% on acquisition proposal from ACS Solutions affiliate. Zhongchao (NASDAQ:ZCMD) +41%. Turquoise Hill Resources (NYSE:TRQ) +31% after receiving Rio Tinto's takeover proposal. Amphastar Pharmaceuticals (NASDAQ:AMPH) +24%. Mullen Autom...